What are the treatment options for Atrial Fibrillation (Afib)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Atrial fibrillation (Afib) treatment typically involves a combination of rate control and rhythm control strategies.

Rate Control

For rate control, beta blockers such as metoprolol (25-100mg twice daily) or calcium channel blockers like diltiazem (30-90mg three times daily) are commonly used 1.

  • These medications are recommended as first-choice drugs in patients with AF and LVEF >40% to control heart rate and reduce symptoms.
  • In patients with AF and LVEF ≤40%, beta-blockers and/or digoxin are recommended to control heart rate and reduce symptoms 1.

Rhythm Control

In cases where rhythm control is desired, anti-arrhythmic medications like amiodarone (400mg three times daily for 1-2 weeks, then 200mg daily) or flecainide (50-100mg twice daily) may be prescribed, often in conjunction with anticoagulation therapy such as apixaban (5mg twice daily) to reduce stroke risk 1.

  • Rhythm control therapy is indicated for symptom improvement in patients with AF, and entails electrical or pharmacological cardioversion of AF in symptomatic patients with persistent or longstanding-persistent AF, long-term antiarrhythmic drug therapy, catheter ablation, AF surgery, ablation, and pacing 1.

Additional Considerations

  • Anticoagulation therapy is recommended for all eligible patients, except those at low risk of incident stroke or thromboembolism (CHA2DS2-VA = 1) 1.
  • Catheter ablation is a reasonable alternative to antiarrhythmic drug therapy for maintaining sinus rhythm, and is considered as a second-line option if antiarrhythmic drugs fail to control AF 1.

From the FDA Drug Label

14 CLINICAL STUDIES 14. 1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation

ARISTOTLE Evidence for the efficacy and safety of apixaban was derived from ARISTOTLE, a multinational, double-blind study in patients with nonvalvular AF comparing the effects of apixaban and warfarin on the risk of stroke and non-central nervous system (CNS) systemic embolism.

The treatment options for Atrial Fibrillation (Afib) include:

  • Anticoagulation therapy: Apixaban is effective in reducing the risk of stroke and systemic embolism in patients with nonvalvular Afib, and is superior to warfarin in this regard 2.
  • Warfarin: Warfarin is also an option for stroke prevention in Afib, although it has a higher risk of major bleeding compared to apixaban 2.

Note: Flecainide may be used for rhythm control in patients with atrial fibrillation, but it is not recommended for patients with chronic atrial fibrillation due to the risk of ventricular pro-arrhythmic effects 3.

From the Research

Treatment Options for Atrial Fibrillation (Afib)

The treatment options for Atrial Fibrillation (Afib) can be broadly categorized into two main strategies: rate control and rhythm control.

  • Rate control refers to the use of atrioventricular nodal blocking medications, including beta blockers and calcium channel blockers, to maintain a goal heart rate 4, 5, 6.
  • Rhythm control, on the other hand, refers to a treatment strategy focused on the use of antiarrhythmic drugs (AAD), cardioversion, and ablation to restore and to maintain a patient in sinus rhythm 4, 5, 7.

Comparison of Rate and Rhythm Control Strategies

Several studies have compared the effectiveness of rate and rhythm control strategies in managing Afib.

  • A randomized, multicenter comparison of these two treatment strategies in patients with Afib and a high risk of stroke or death found that management of Afib with the rhythm-control strategy offers no survival advantage over the rate-control strategy, and there are potential advantages, such as a lower risk of adverse drug effects, with the rate-control strategy 7.
  • A meta-analysis of randomized controlled trials comparing rate and rhythm control strategies in patients with Afib found that a strategy of ventricular rate control, in combination with anticoagulation in appropriate patients, appears to be at least equivalent to a strategy of maintaining sinus rhythm by using currently available antiarrhythmic drugs in preventing clinical outcomes 8.

Anticoagulation Therapy

Anticoagulation therapy is an important aspect of Afib management, regardless of whether a rate or rhythm control strategy is employed.

  • Anticoagulant drugs are recommended for use in both approaches to prevent thromboembolism 4, 7.
  • The majority of strokes in patients with Afib occur after warfarin has been stopped or when the international normalized ratio is subtherapeutic 7.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.